BCAP31

B-cell receptor-associated protein 31 · P51572 · BCAP31 on Sugi Atlas →

0 patent compounds predicted against BCAP31, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to BCAP31 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Fludarabine With or Without Cyclophosphamide in Treating Patients With Chronic Lymphocytic Leukemia PHASE3COMPLETED
A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies PHASE1/PHASE2UNKNOWN
A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors PHASE1RECRUITING
Study of BCMA/CD70 CAR-T Therapy for Refractory cSLE PHASE1RECRUITING
Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia PHASE1COMPLETED
Phase I Study of Novel Estrogen Receptor(ER) a36 Modifier Icaritin in Advanced Breast Cancer Patients PHASE1UNKNOWN
A Study of CTA30X Cell Injection in Patients With Relapsed or Refractory CD19-positive B-line Hematological Malignancies EARLY_PHASE1COMPLETED
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia nanUNKNOWN
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia nanNOT_YET_RECRUITING
Expression of CD19 Complex in Lymphoproliferative Disorders nanUNKNOWN
Dietary Intervention With High Phenolic EVOO in CLL nanCOMPLETED
Genetic Studies of Inflammatory Bowel Disease nanCOMPLETED
Comparison of the Breast Tumor Microenvironment nanACTIVE_NOT_RECRUITING
Family Blood Pressure Program - SAPPHIRe Network nanCOMPLETED
Using of Costimulatory and co Inhibatory Immune Checkpoints as Diagnostic and Prognostic in Breast Cancer nanUNKNOWN
Characterization of Breg Cells nanCOMPLETED
Clinical Validation of an Immunocytochemistry Method Using MARS1 nanCOMPLETED
Implication of CCR4-NOT Complex Subunit 7 Expression in Natural Killer Cell Resistance in Metastatic Breast Cancer nanCOMPLETED
New Biomarkers for Diagnosis and Follow-up of Patients With LRBA or CTLA4 Deficiencies nanUNKNOWN
Genomic Evaluation in Patients With Diffuse Large B Cell Lymphoma After First Relapse/Progression nanUNKNOWN
Development of a New Immunochemistry Method Using Antibodies of Proteins Related Bile Duct Cancer nanCOMPLETED
Protein Expression as a Potential Diagnostic Biomarker of Cervical Dysplasia and/or Cancer nanCOMPLETED
Assessment of Candidate Protein Expression in Breast Cancer Specimens nanCOMPLETED
Predictive Role of New Biomarkers for Hypersensitive Patients to Radiation in Breast Cancer (BIORISE) nanACTIVE_NOT_RECRUITING
Neutrophils as Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener's Granulomatosis) nanCOMPLETED
sCD163 & CD19 as Candidate Biomarkers in CIDP and MMN nanUNKNOWN
Blood-based Biomarkers for the Prognosis of Sports Related Concussion nanCOMPLETED
Genetic Characterization of Parkinson's Disease nanCOMPLETED
Genetic Architecture of Chronic Inflammatory Demyelinating Polyradiculoneuropathy nanUNKNOWN
Study of Blood Samples From High-Risk Postmenopausal Women Who Received Treatment on Breast Cancer Prevention Clinical Trials NSABP-P-1 or NSABP-P-2 nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a BCAP31 binder may also engage these)

ProteinNameSimilarity
Q5R8H3 1.000 Q5R8H3 →
Q61335 1.000 Q61335 →
Q32KL9 0.997 Q32KL9 →
Q5R9U7 0.996 Q5R9U7 →
Q9UHQ4 0.995 Q9UHQ4 →
Q61334 0.993 Q61334 →
O14290 0.987 O14290 →
P70403 0.986 P70403 →
Q07451 0.986 Q07451 →
Q54K74 0.985 Q54K74 →
Q2KI89 0.983 Q2KI89 →
Q8SYD0 0.983 Q8SYD0 →
Q5R629 0.983 Q5R629 →
Q4I7N9 0.983 Q4I7N9 →
Q0IG18 0.982 Q0IG18 →
Q24276 0.982 Q24276 →
P91928 0.982 P91928 →
Q04210 0.982 Q04210 →
Q9U2Y2 0.982 Q9U2Y2 →
Q9ERA6 0.982 Q9ERA6 →
Q6Z6S1 0.982 Q6Z6S1 →
G5EF60 0.981 G5EF60 →
O02328 0.981 O02328 →
Q24185 0.981 Q24185 →
Q7ZYV9 0.981 Q7ZYV9 →
Q28FG4 0.981 Q28FG4 →
Q17AF4 0.981 Q17AF4 →
A1XD95 0.981 A1XD95 →
Q99961 0.981 Q99961 →
Q9FG01 0.981 Q9FG01 →